The short version of incretin fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-02-22 and is reviewed periodically as new material appears.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
| Property | Value | Notes |
|---|---|---|
| Receptor targets | GIP, GLP-1, glucagon | One molecule activates all three pathways |
| Research identifier | LY3437943 | Code used in published trial reports |
| Development stage | Phase 3, reported as ongoing | Not approved by any regulatory agency |
| Route studied | Subcutaneous | Administration form used in clinical trials |
| Studied populations | Adults with obesity or type 2 diabetes | Enrollment criteria vary between trials |
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
冻干粉通常在低温环境下保存，复溶之后需要按指定条件在较短时间内使用。反复冻融和剧烈振荡可能促进聚集，低吸附容器则能减少多肽在管壁上的损失。批号、日期与处理条件的完整记录，是后续复核与问题追溯的基础。
供应环节涉及来源核实与文件审核两类工作。分析证书、批次记录以及第三方检测报告构成常见的可追溯材料。来源不清的样品很难确认身份与纯度，因此核实步骤在实际操作中具有明确意义。缺少方法细节的报告通常无法复核。
Finally, they contend that remote administration may result in an increased risk that insufficient amounts of the lethal-injection drugs enter the inmate's bloodstream. In summary, opponents argue that the effect of dilution or of improper administration of thiopental is that the inmate dies an agonizing death through suffocation due to the paralytic effects of pancuronium bromide and the intense burning sensation caused by potassium chloride. Opponents of lethal injection, as practiced, argue that the procedure is designed to create the appearance of serenity and a painless death, rather than actually providing it. Specifically, opponents object to the use of pancuronium bromide, arguing that it serves no useful purpose in lethal injection since the inmate is physically restrained. Therefore, the default function of pancuronium bromide would be to suppress the autonomic nervous system, specifically to stop breathing.
=== Modern ciders === Modern ciders are made from culinary apples and are lower in tannins and higher in acidity than other cider styles. Common culinary apples used in modern ciders include McIntosh, Golden Delicious, Jonagold, Granny Smith, Gala, and Fuji. A sweet or low alcohol cider may tend to have a strong aromatic and flavour character of apple, while drier and higher alcohol ciders will tend to produce a wider range of fruity aromas and flavours. Modern ciders vary in color from pale to yellow and can range from brilliant to a hazy clarity. Clarity can be altered through various cider making practices, depending on the cider maker's intentions. There are even Rosé ciders from apples where the skins and flesh are red.
Another factor affecting the treatment response is the generation of antibodies against the infused enzyme, which is particularly severe in Pompe infants who have a complete deficiency of the acid alpha-glucosidase. Immune tolerance therapy to eliminate these antibodies has improved the treatment outcome. A Late Onset Treatment Study (LOTS) was published in 2010. The study was undertaken to evaluate the safety and efficacy of aglucosidase alfa in juvenile and adult patients with Pompe disease. LOTS was a randomized, double-blind, placebo-controlled study that enrolled 90 patients at eight primary sites in the United States and Europe. Participants received either aglucosidase alfa or a placebo every other week for 18 months. The average age of study participants was 44 years. The primary efficacy endpoints of the study sought to determine the effect of Myozyme on functional endurance as measured by the six-minute walk test and to determine the effect of aglucosidase alfa on pulmonary function as measured by percent predicted forced vital capacity. The results showed that, at 78 weeks, patients treated with aglucosidase alfa increased their distance walked in six minutes by an average of approximately 25 meters as compared with the placebo group which declined by 3 meters (P=0.03). The placebo group did not show any improvement from baseline. The average baseline distance walked in six minutes in both groups was approximately 325 meters. Percent predicted forced vital capacity in the group of patients treated with aglucosidase alfa increased by 1.2 percent at 78 weeks.
In exchange for the Syndicate's cooperation, the Colonists handed over alien embryos as a source of genetic material for the hybrid experiments, as well as allowing limited military use of their technology and resources (such as the Alien Bounty Hunters), and promising that the heirs of the Syndicate members, who were turned over to the Colonists as an act of good faith, would survive the takeover. Meanwhile, both sides had a secret. The human conspirators would attempt to develop a vaccine for the alien virus in an effort to save all of humanity. The Colonists pretended that mass infection of humanity by the black oil would make them a controlled slave race, but in reality the oil would give birth to new alien beings within the human hosts resulting in re-population rather than colonization.
Sources: en.wikipedia.org
=== Economic miracle === The West German Wirtschaftswunder ("economic miracle", coined by The Times) began in 1950. This improvement was sustained by the currency reform of 1948 which replaced the Reichsmark with the Deutsche Mark and halted rampant inflation. The Allied dismantling of the West German coal and steel industry finally ended in 1950.
At high pressures, above approximately 10 GPa and temperatures of a few hundred kelvin or less, α-iron changes into another hexagonal close-packed (hcp) structure, which is also known as ε-iron. The higher-temperature γ-phase also changes into ε-iron, but does so at higher pressure. The physical properties of iron at very high pressures and temperatures have been studied extensively because of their relevance to theories about the cores of the Earth and other planets. The Earth's inner core is generally presumed to consist of an iron-nickel alloy with ε (or β) structure. Some controversial experimental evidence exists for a stable β phase at pressures above 50 GPa and temperatures of at least 1500 K. It is supposed to have an orthorhombic or a double hcp structure. (Confusingly, the term "β-iron" is sometimes also used to refer to α-iron above its Curie point, when it changes from being ferromagnetic to paramagnetic, even though its crystal structure has not changed.)
In the tropics and sub-tropics, relatively more species are expanding due to human activities, particularly due to the spread of crops such as rice whose expansion in south Asia has benefitted at least 64 bird species, though may have harmed many more species.
Draculin is a noncompetitive, tight-binding inhibitor of FXa. The inhibition upon contact with the blood of the victim is immediate. Draculin forms equimolar complexes with factor FXa. The formation of Draculin-factor Xa is a two-stage process. The first reversible stage is characterized by the following constants: k1 = 1.117*106 M-1*sec-1, k-1 = 15.388*10-1 sec-1. The second irreversible (concentration-independent) stage is characterized by the forward reaction rate constant k2 = 0.072 sec-1. The dissociation constant is determined as the ratio k-1/k1 = 13.76 nM. Because of the immediate inhibition, the reaction is not readily reversible initially, but is a reversible reaction. It does not act on thrombin, trypsin or chymotrypsin and does not express fibrinolytic activity. The protein increases the lag phase as well as the height of the peak of thrombin generation when in plasma, leading to prolonged bleeding. The biological activity of Draculin is highly dependent on glycosylation of the native protein and can be severely affected by the salivation pattern of the animals.
=== Environmental issues === On January 23, 2019, Pritzker committed Illinois to the United States Climate Alliance, which aimed to reduce the state's greenhouse gas emissions by over 26% by 2025. In 2017, it was revealed that both Pritzker and his 2018 gubernatorial primary opponent Christopher G. Kennedy held stock in ExxonMobil, Chevron Corporation, Occidental Petroleum, and ConocoPhillips. In 2024, Pritzker signed the SAFE CCS Act, making Illinois the second state after California to halt approval of carbon dioxide pipelines.
Sources: en.wikipedia.org
Durham County Council itself became a unitary authority on 1 April 2009, when the seven remaining non-metropolitan districts of the county were abolished and the county council absorbed their functions. The legislation which made the county council a unitary authority allowed the council to omit the word 'County' from its name to become 'Durham Council', but in the event the name 'Durham County Council' was kept. In 2024 a combined authority was established covering Durham, Gateshead, Newcastle upon Tyne, North Tyneside, Northumberland, South Tyneside and Sunderland, called the North East Mayoral Combined Authority. It is chaired by the directly elected Mayor of the North East and oversees the delivery of certain strategic functions across the area.
Throughout the times, there have been a variety of architectural styles, from those of indigenous peoples to contemporary ones, passing through colonial (military and religious), Republican, transition and modern styles.
=== (2) Separation and quantification methods === Separation methods are the first step to decomplexify the venom sample, with a common method being reverse‐phase high performance liquid chromatography (RP-HPLC). This method can be applied broadly to nearly all venoms as a crude fractionation method and to detect the peptide bonds found. A less common techniques like 1D/2D gel electrophoresis can also be used in cases of venoms containing heavy, complex peptides (Preferable >10KDa). This means in additions to RP-HPLC, Gel electrophoresis can help identify large molecules (such as enzymes) and to help refine venom prior to further analytical methods. Next, N-terminal sequencing is used to find the amino acid order of the fractionated proteins/peptides starting with the N-terminal end. Furthermore, SDS‐PAGE (Sodium dodecyl sulfate-polyacrylamide gel electrophoresis) can be performed on the isolated proteins from the RP-HPLC to identify proteins of interest before moving on to the identification stage.
King Crimson toured to support both albums, including double bill shows with Tool. The tour was documented on the live album Heavy ConstruKction in 2000 and the Heaven & Earth (1997–2008) box set in 2019. Led Zeppelin bassist John Paul Jones and his band supported Crimson on some live shows. On 9 November 2001, King Crimson released a limited edition live EP called Level Five, featuring three new pieces: "Dangerous Curves", "Level Five" and "Virtuous Circle", plus versions of "The ConstruKction of Light" and ProjeKct's "The Deception of the Thrush", followed by an unlisted track called "ProjeKct 12th and X" after one minute of silence. A second EP followed in October 2002, Happy with What You Have to Be Happy With. This featured eleven tracks (including a live version of "Larks' Tongues in Aspic, Part IV"). Half of the tracks were processed vocal snippets by Belew, and the songs themselves varied between Soundscapes, gamelan, heavy metal and blues. The double duo line-up released King Crimson's thirteenth album, The Power to Believe, in March 2003. Fripp described it as "the culmination of three years of Crimsonising". The album incorporated, reworked and retitled versions of "Deception of the Thrush" ("The Power to Believe III"), tracks from their previous two EPs, and an extract from a Fripp Soundscape with added instrumentation and vocals, alongside "Level Five" (the final installment of the "Larks' Tongues in Aspic" suite). The Power to Believe reached No. 162 in the UK and No. 150 in the US.
Sources: en.wikipedia.org
It is a synthetic peptide triagonist that engages GIP, GLP-1, and glucagon receptors. Investigational compounds in this class are studied for metabolic conditions rather than for a single organ system.
No regulatory agency has approved it for any indication. It remains an investigational product studied within controlled clinical trial programs.
A dual agonist engages two receptor targets, typically GIP and GLP-1. A triagonist adds glucagon receptor activity, which is intended to influence energy expenditure alongside appetite and glucose handling.
As of the mid-2020s retatrutide remains investigational and is not an approved medicine in the United States or the European Union. It has been supplied mainly to participants in clinical trials. Labels and availability can change, so regulatory listings should be checked directly.